IN BRIEF: Amryt Pharma delists from AIM as trading shifts to New York

Amryt Pharma PLC - Dublin, Ireland and Boston, Massachusetts-based biopharmaceutical firm focused on rare diseases - Shares delisted from AIM in London on Tuesday but remain trading on Nasdaq Global Select Market in New York. Back in November, Amryt had announced plans to remove its shares from AIM, saying that having a single listing on Nasdaq should improve trading liquidity. It noted at the time that 87% of the trading in its shares in the month prior had been in the form of American depositary shares in New York. This was partly the result of its acquisition of US-listed Chiasma Inc back in May of last year.

Current stock price on Nasdaq: USD10.20, up 1.5% on Tuesday

12-month change: down 24%

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.